1810A-045 (81841.0192)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Robert S. Matson

Serial No:

09/872,052

Filed: May 31, 2001

For:

IMMOBILIZATION OF UNMODIFIED

BIOPOLYMERS TO ACYL FLUORIDE

ACTIVATED SUBSTRATES

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS

Box Sequence Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Notice to Comply dated February 26, 2003, Applicant would like to note that the statement CRF does not match application specification (#7) in the Notice to Comply was in error. In our telephone conversation with Anne-Marie Corrigan, of USPTO, she stated that the original CRF was never analyzed for its content, because it was melted and Applicant is just required to submit a CRF substitute for the original CRF. Accordingly, enclosed are the following: a substitute computer-readable disc containing the Sequence Listing for the above-noted case generated by PatentIn v.3.1 software in the text format, a printout of the Sequence Listing and a statement verifying its contents and verifying that the content of the paper and computer-readable copies of the Sequence listing filed herewith are the same. No new matter has been added.

A copy of the Notice to Comply is enclosed herewith, as requested by the Examiner; as well as a copy of the CRF problem report facsimile. The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment to our Deposit Account No. 50-1314.

Art Unit: 1641

Examiner: Gabel, Gailene

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed

Commissioner for Patents Washington D.C. 20231, on

March 25, 2003 Date of Deposit

Wei-Ning Yang, Reg. No. 38,690

Name

Signature

APR 0 2 2003

TECH CENTER 1600/2900

If for any reason the Examiner finds the application other than in condition for allowance, the Examiner is requested to call the undersigned attorney at the Los Angeles, California telephone number (213) 337-6700 to discuss the steps necessary for placing the application in condition for allowance.

Respectfully submitted,

HOGAN & HARTSON L.L.P.

By:

Wei-Ning Yang

Registration No. 38,690 Attorney for Applicant(s)

Date: March 25, 2003

500 South Grand Avenue, Suite 1900 Los Angeles, California 90071

Phone: 213-337-6700 Fax: 213-337-6701

Notice to Comply MAR 3 1 2003 Gailene R. Gabel **DISCLOSURES**

Applicati	n	No.
09/872,	05	2
Exami	ne	r

Applicant(s) Matson, Robert

Art Unit 1641

OTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

Applicant Must Provide:			
\boxtimes	7. Other: CRF does not match application specification.		
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).		
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).		
Ø	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."		
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).		
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).		
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).		

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212


Patent Software Program Support

Technical Assistance......703-287-0200

To Purchase Patent Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit:

Examiner:

1641

Gabel, Gailene

In re application of: Robert S. Matson Serial No: 09/872.052

Filed: May 31, 2001

IMMOBILIZATION OF UNMODIFIED BIOPOLYMERS TO ACYL FLUORIDE ACTIVATED SUBSTRATES

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Transmitted herewith is an amendment in the above-identified application. Also enclosed are:

 \boxtimes Response to Notice to Comply With Sequence Listing Requirements \boxtimes Copy of Notice to Comply With Requirements...;

 \boxtimes Diskette containing sequence listing;

 \boxtimes Print out of Sequence Listing; and

 \boxtimes Verified Statement Concerning Sequence Listing.

 \boxtimes No additional fee is required.

A check in the amount of \$___ to cover the additional claims fee is enclosed. A copy of this sheet is enclosed.

A check in the amount of \$ to cover the extension fee is enclosed. A copy of this sheet is enclosed.

 \boxtimes The Commissioner is hereby authorized to charge any deficiencies of fees associated with this communication or credit any overpayment to Deposit Account No. 50-1314. A copy of this sheet is enclosed.

Any filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims \boxtimes

Any patent application processing fees under 37 C.F.R. § 1.17

Date: March 25, 2003

Biltmore Tower

500 South Grand Avenue, Suite 1900

Los Angeles, California 90071 Telephone: 213 337-6700 Facsimile: 213 337-6701

Wei-Ning Yang

Respectfully submitted. HOGAN & HARTSON L.L.P.

> Registration No. 38,690 Attorney for Applicant(s)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents

Washington D.C. 20231, on March 25, 2003 Date of Deposit

Wei-Ning Yang, Reg. No. 38,69

Name 3/25/03 Signature Date

RECEIVED

APR 0 2 2003

TECH CENTER 1600/2900